
Monday, April 01, 2024 11:51:51 AM
Sintx is still a public company so if Sintx going puiblic was a giant con to fund R&D and go private again, then the scam isnt complete and theres still time to stop it. The only con going on atm, is the one being used to scare investors away through continued naked shorting of offerings to drive the price lower combined with constant posts on forums the company is a scam. Again, there has been nothing to justify the drop in stockprice since late 2022 other than that. If Sintx was properly valued then this wouldnt be an issue. The con is that Sintx isnt worth investing in whether management is part of this or not. The goal seems to be to create the context to acquire Sintx, or its IP, cheap and then make a boat ton private when deals suddenly appear. The fact that management purposefully did not disclose and removed the fact that Dr Bal and Dr Link were connected to Zimmer in the companies IPO paperwork is a redflag that they could be part of keeping Sintx from being successful publicly. Those facts were very much there when Sintx tried to IPO for a proper valuation ($225m if memory services) in 2007. 225m valuation when it had only 3 product candidates. Now so many more exist.
Sintx-Zimmer Connection
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053353
Management Ties to Zimmer omitted from the 2013 IPO paperwork
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174144294
Sintx-Biomet R&D
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053136
Dr. Pezzotti member of Sintx scientific board and his research for Biomet
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660
Zimmer Biomet Hires Si3N4 Coatings Expert
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174115529
Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.
One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
========================================
Extra information on the status of a Si3n4 based hip implant:
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/
========================================
Electromagnetic fields, metal implant corrosion, and dis-ease it causes

https://i.imgur.com/nLg7SXT.jpg
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779
Could it be that there is a strategy to distract people away from looking at the basic data?
Is all this an exercise to create more and more forum verbiage to drown out any serious discussion of evidence?
Recent SINT News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/28/2025 04:15:24 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/25/2025 08:15:48 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/19/2025 09:15:41 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/19/2025 12:00:35 PM
- SINTX Technologies Announces Publication of Study Confirming Superior Performance of Silicon Nitride in Cervical Spine Fusion • GlobeNewswire Inc. • 03/19/2025 12:00:00 PM
- Sintx Technologies Announces Board Chairman Transition • GlobeNewswire Inc. • 03/17/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/27/2025 03:46:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2025 01:30:29 PM
- SINTX Technologies Announces $5 Million Private Placement Priced At-the-Market under Nasdaq Rules • GlobeNewswire Inc. • 02/26/2025 01:00:00 PM
- SINTX Technologies Sells Technology Assesment and Transfer Subsidiary to Focus on Medical Device Market • GlobeNewswire Inc. • 02/20/2025 11:15:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2025 11:10:05 AM
- This Healthcare Stock Rose Sharply On USPTO Issuance • AllPennyStocks.com • 02/19/2025 07:10:00 PM
- SINTX Receives Issuance of U.S. Patent for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic Biomaterial • GlobeNewswire Inc. • 02/19/2025 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/14/2025 10:08:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2024 09:15:30 PM
- SINTX Technologies Secures Patent Allowance for Wide-Ranging Silicon Nitride Biomaterial Applications • GlobeNewswire Inc. • 12/17/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2024 09:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2024 06:15:19 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/26/2024 11:10:12 AM
- SINTX Technologies and NED Medical Partner to Advance Cutting-Edge Ceramic Microsphere Medical Devices for Cancer Treatment • GlobeNewswire Inc. • 11/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/19/2024 10:13:22 PM
- SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer • GlobeNewswire Inc. • 11/19/2024 11:00:00 AM
FEATURED NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market • Mar 27, 2025 11:20 AM
FEATURED LaFleur Minerals Announces Memorandum of Understanding with Granada Gold on Milling Assessment for the Granada Gold Project Using the Beacon Gold Mill • Mar 27, 2025 8:40 AM
FEATURED Nightfood Holdings (NGTF) Issues Shareholder Update on Imminent Strategic Acquisitions and Rapid Expansion in AI-Powered Hospitality Automation • Mar 27, 2025 8:30 AM
ConnectM Secures Landmark Home and Building Electrification Project in India, Marking Strategic International Expansion • CNTM • Mar 27, 2025 7:05 AM
$SYNX - Could Silynxcom Be the Next 1000% Israeli Defense Tech Rocketship? (NYSE: SYNX) • SYNX • Mar 26, 2025 12:15 PM
ConnectM Issues Stockholder Letter from CEO & Chairman • CNTM • Mar 26, 2025 12:14 PM